Flindr Therapeutics
Jac Wijkmans is an accomplished professional in the pharmaceutical and life sciences sectors, currently serving as Chief Scientific Officer at Flindr Therapeutics since November 2021. Wijkmans also operates as the Owner and Principal Consultant at INNTREST Consultancy BV, providing strategic R&D advice and project management services since January 2014. Previous roles include Senior Program Manager BioConjugates at Lonza, R&D Consultant at Immagene, and leadership positions in various organizations focused on gene therapy, immunotherapy, and drug development. Wijkmans holds a PhD in Organic Chemistry from Leiden University and has a robust educational background in Bio-Organic Chemistry and Chemistry, complemented by extensive experience in business development and project management in the life sciences industry.
This person is not in any teams
Flindr Therapeutics
Flindr Therapeutics, based in Oss in the Netherlands, is a private pre-clinical biotech company developing next-generation precision oncology treatments. The Company, previously called Immagene, was spun out of the Netherlands Cancer Institute (NKI) and Oncode Institute in 2020, by founders Prof Daniel Peeper, Prof Christian Blank and Dr Maarten Ligtenberg. Flindr is actively building a pipeline of highly promising, first-in-class precision oncology therapies identified through the ImmunoGram Drug Discovery Engine. It is backed by V-Bio Ventures, Johnson & Johnson Innovation – JJDC, Inc., QBIC Fund, Flanders Future Tech Fund, Curie Capital, Oncode Oncology Bridge Fund, Swanbridge, Innovatiefonds Noord Holland, and BOM. Flindr has entered into a research collaboration with the NKI, and the VIB (Flanders Institute of Biotechnology).